Project Grant K23HL174588
Award Date
9/17/24
Completion Date
8/31/29
Dollars Obligated
$192K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $156,340 in funding to Connecticut Children's Medical Center to develop and test a communication-enhancement intervention for healthcare providers (HCPs) to improve health outcomes in pediatric sickle cell disease (SCD) patients. The 5-year award period runs from June 15, 2025 to May 31, 2030. The key activities include refining an...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $154,796 to Vanderbilt University Medical Center to utilize non-invasive neuroimaging methods to investigate cerebral oxygen utilization in adults with sickle cell disease (SCD). The research aims to: 1) assess how treatment-induced increases in hemoglobin levels impact cerebral blood flow and arterial-to-venous transit times in SCD...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, provides $402,117 to the University of North Carolina at Chapel Hill. The award will support the adaptation and pilot testing of a family-centered intervention, SUCCEED-ICU, designed to improve long-term outcomes for survivors of acute respiratory failure. The project aims to: 1) adapt the existing SUCCEED intervention for use in acute respiratory...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
This $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc., a minority-owned small business in Detroit, Michigan. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system to assess red blood cell sickling under hypoxic conditions as an indicator of sickle cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $254,604 to Dana-Farber Cancer Institute, Inc. to develop and implement a community-based collaborative care model to deliver a resilience-focused intervention for adolescents and young adults with non-malignant blood disorders, such as sickle cell disease. The 5-year project aims to (1) assess the feasibility and acceptability of the...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a $496,503 research study at the University of Pennsylvania Clinical Practices examining sex and gender influences on inflammation and pain in sickle cell disease (SCD). The objectives are to (1) ascertain sex- and gender-related mechanisms of perimenstrual vaso-occlusive pain episodes (VOEs) in SCD, and (2) determine the therapeutic effectiveness of the...